These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 33812679)

  • 1. Cardiac substrate utilization in heart failure: Where is the relevance of SGLT2 inhibition?
    Mann PA; Lehrke M
    J Thorac Cardiovasc Surg; 2022 Sep; 164(3):895-899. PubMed ID: 33812679
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment with sodium-glucose cotransporter-2 inhibitors in heart failure patients: The potential benefits of monitoring FGF-23 levels?
    Gruson D; Pouleur AC; Hermans MP; Ahn SA; Rousseau MF
    Ann Endocrinol (Paris); 2022 Feb; 83(1):78-80. PubMed ID: 34728212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Commentary: Benefits of SGLT2 inhibition in heart failure: A bellwether for importance of other metabolic pathways.
    Ferraris VA
    J Thorac Cardiovasc Surg; 2022 Sep; 164(3):900-901. PubMed ID: 33894999
    [No Abstract]   [Full Text] [Related]  

  • 4. Healthcare disparities in heart failure patients (with and without type 2 diabetes) and use of sodium glucose co-transport inhibitors (SGLT2-i).
    Madan S; Farooq M; Diab K; Melainis AA; DiPalo KE; Crandall JP; Rodriguez CJ; Jorde UP
    Endocrine; 2022 Feb; 75(2):654-658. PubMed ID: 34755315
    [No Abstract]   [Full Text] [Related]  

  • 5. Focused Updates: SGLT2 Inhibitors in Patients With Heart Failure and/or Chronic Kidney Disease.
    Cheng JWM; Colucci V; Kalus JS; Spinler SA
    Ann Pharmacother; 2021 Feb; 55(2):252-260. PubMed ID: 32536199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SGLT2 inhibitors reduce infarct size in reperfused ischemic heart and improve cardiac function during ischemic episodes in preclinical models.
    Andreadou I; Bell RM; Bøtker HE; Zuurbier CJ
    Biochim Biophys Acta Mol Basis Dis; 2020 Jul; 1866(7):165770. PubMed ID: 32194159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of SGLT2 inhibition on imaging markers of cardiac function: A systematic review and meta-analysis.
    Theofilis P; Antonopoulos AS; Katsimichas T; Oikonomou E; Siasos G; Aggeli C; Tsioufis K; Tousoulis D
    Pharmacol Res; 2022 Jun; 180():106243. PubMed ID: 35523389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renal and Cardiovascular Effects of sodium-glucose cotransporter 2 (SGLT2) inhibition in combination with loop Diuretics in diabetic patients with Chronic Heart Failure (RECEDE-CHF): protocol for a randomised controlled double-blind cross-over trial.
    Mordi NA; Mordi IR; Singh JS; Baig F; Choy AM; McCrimmon RJ; Struthers AD; Lang CC
    BMJ Open; 2017 Oct; 7(10):e018097. PubMed ID: 29042392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sodium Glucose Cotransporter-2 Inhibition for Acute Myocardial Infarction: JACC Review Topic of the Week.
    Udell JA; Jones WS; Petrie MC; Harrington J; Anker SD; Bhatt DL; Hernandez AF; Butler J
    J Am Coll Cardiol; 2022 May; 79(20):2058-2068. PubMed ID: 35589167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Obesity, heart failure, and SGLT2 inhibition: DECLARE-TIMI 58 provides insights.
    Sattar N; Anker SD; Butler J; Verma S
    Eur Heart J; 2022 Aug; 43(31):2968-2970. PubMed ID: 34618015
    [No Abstract]   [Full Text] [Related]  

  • 11. Cardiac mechanisms of the beneficial effects of SGLT2 inhibitors in heart failure: Evidence for potential off-target effects.
    Dyck JRB; Sossalla S; Hamdani N; Coronel R; Weber NC; Light PE; Zuurbier CJ
    J Mol Cell Cardiol; 2022 Jun; 167():17-31. PubMed ID: 35331696
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of Protective Effects of SGLT2 Inhibitors in Cardiovascular Disease and Renal Dysfunction.
    Liu B; Wang Y; Zhang Y; Yan B
    Curr Top Med Chem; 2019; 19(20):1818-1849. PubMed ID: 31456521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SGLT2 inhibition and heart failure-current concepts.
    Custodio JS; Duraes AR; Abreu M; Albuquerque Rocha N; Roever L
    Heart Fail Rev; 2018 May; 23(3):409-418. PubMed ID: 29704192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insulin resistance and heart failure during treatment with sodium glucose cotransporter 2 inhibitors: proposed role of ketone utilization.
    Hattori Y
    Heart Fail Rev; 2020 May; 25(3):403-408. PubMed ID: 31960270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments.
    Garcia-Ropero A; Badimon JJ; Santos-Gallego CG
    Expert Opin Drug Metab Toxicol; 2018 Dec; 14(12):1287-1302. PubMed ID: 30463454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SGLT2 inhibitors break the vicious circle between heart failure and insulin resistance: targeting energy metabolism.
    Wang X; Ni J; Guo R; Li L; Su J; He F; Fan G
    Heart Fail Rev; 2022 May; 27(3):961-980. PubMed ID: 33713009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Do sodium-glucose co-transporter-2 inhibitors prevent heart failure with a preserved ejection fraction by counterbalancing the effects of leptin? A novel hypothesis.
    Packer M
    Diabetes Obes Metab; 2018 Jun; 20(6):1361-1366. PubMed ID: 29359851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new class of drugs for heart failure: SGLT2 inhibitors reduce sympathetic overactivity.
    Sano M
    J Cardiol; 2018 May; 71(5):471-476. PubMed ID: 29415819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Bioinformatics Investigation into the Pharmacological Mechanisms of Sodium-Glucose Co-transporter 2 Inhibitors in Diabetes Mellitus and Heart Failure Based on Network Pharmacology.
    Mai Z; Li H; Chen G; Chen E; Liu L; Lun Z; Lai W; Zhou C; Yu S; Liu J; Chen S; Chen J; Liu Y
    Cardiovasc Drugs Ther; 2022 Aug; 36(4):713-726. PubMed ID: 34028657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploration of the clinical benefits of sodium glucose co-transporter 2 inhibitors in diabetic patients with concomitant heart failure.
    Tanaka A; Node K
    Cardiovasc Diabetol; 2018 May; 17(1):74. PubMed ID: 29801492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.